Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 7 | BMC Cancer

Fig. 7

From: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Fig. 7

FRAX597 combined with gemcitabine inhibits tumour volume and increases survival in vivo. Pan02 murine pancreatic cancer cells were injected orthotopically into the tail (a-b) or head (c) of the pancreas of C57/Bl6 mice. Mice were treated with saline (control; CT), FRAX597 (FRAX), gemcitabine (Gem), or FRAX597 and gemcitabine (Gem + FRAX) at the doses given in the Materials and Methods section by intraperitoneal injection. Mice were euthanased after 30 days for the orthotopic pancreatic tail model and tumour volumes were measured (a), and scored for the presence of peritoneal carcinomatosis, or peritoneal spread (b). For assessment of survival, mice were euthanased after achieving a poor health score and the time to euthanasia plotted as a collated Kaplan-Meier curve (c). The data represent mean ± SEM. * p < 0.05, *** p < 0.001, compared to control. # p < 0.05 compared to gemcitabine treatment. ^^^ p < 0.001 compared to combination treatment (Gem + FRAX) using stratified Cox regression analysis

Back to article page